Alignment Stock Surges After 2.48% Medicare Rate Hike
Alignment Healthcare (ALHC) stock surged after the U.S. government announced a 2.48% Medicare Advantage and Part D payment rate hike for 2027, with an effective increase closer to 5% due to risk-scoring adjustments. This reversal from an earlier flat reimbursement proposal is seen as a significant win for insurers, particularly as regulators also delayed certain risk-model changes. Technical analysis shows positive short-term and intermediate trends for ALHC, with analysts maintaining a Buy rating and increased price targets.
Alignment Healthcare, Centene, CVS Health, Elevance Health, and Clover Health Stocks Trade Up, What You Need To Know
Several health insurance provider stocks, including Alignment Healthcare, Centene, CVS Health, Elevance Health, and Clover Health, saw significant jumps after the government announced a surprise increase in Medicare Advantage payment rates. This change is expected to improve profit margins for these companies by increasing revenue from federal funds without raising costs. Alignment Healthcare, in particular, experienced an 18.7% jump, contributing to its 9.3% gain since the start of the year and bringing it close to its 52-week high.
Alignment Healthcare Stock Rockets 18% as Medicare Advantage Growth Momentum Ignites Investor Rally
Shares of Alignment Healthcare Inc. surged over 18% on Tuesday, fueled by investor optimism surrounding its Medicare Advantage model, strong membership growth, and improving profitability. The company has demonstrated impressive year-over-year membership gains and exceeded financial guidance, despite broader sector reimbursement pressures. Analysts maintain a "Buy" rating, anticipating further upside as Alignment Healthcare prepares for upcoming financial presentations.
Alignment Healthcare Jumps More Than 16% During the Day – What’s Driving This Rally?
Alignment Healthcare (ALHC) experienced a significant intraday jump of over 16%, reaching $21.74, driven by strong technical momentum and a broader rally in the healthcare sector. The stock's short-term bullish trend and breaking above key moving averages suggest a potential breakout, despite mixed past performance and some valuation concerns. Traders are exploring high-leverage options to capitalize on this rally, particularly if the stock sustains above $22.50.
Alignment Healthcare (NASDAQ: ALHC) insider files to sell 27,198 shares
An insider at Alignment Healthcare (NASDAQ: ALHC) has filed a Form 144 notice to sell 27,198 shares of common stock. These shares were acquired on June 4, 2025, through the vesting of restricted stock units under the company's 2021 Equity Incentive Plan. This filing signals an intent to sell but does not confirm that the sale has already occurred or provide details on the sale price or proceeds.
A Look At Alignment Healthcare (ALHC) Valuation After Earnings Beat And Cautious Revenue Guidance
Alignment Healthcare (ALHC) recently reported strong quarterly results, exceeding revenue and earnings expectations, yet cautious revenue guidance for the next quarter caused an 8.5% stock drop. Despite a significant 3-year shareholder return and an analyst-suggested intrinsic discount, investors are advised to carefully assess if a buying opportunity exists or if the market has already factored in future growth. The company's valuation relies on a narrative of robust technology-enabled care, investments in automation, and improved scalability, but faces risks from Medicare Advantage policy and competitive member growth.
We Might See A Profit From Alignment Healthcare, Inc. (NASDAQ:ALHC) Soon
This article discusses the financial outlook for Alignment Healthcare, Inc. (NASDAQ:ALHC), focusing on its path to profitability. Analysts project the company to become profitable within the next two years, significantly outpacing the industry average. The analysis highlights key factors such as consistent revenue growth and decreasing losses per share, suggesting a positive financial trajectory for ALHC.
Does Alignment Healthcare's (ALHC) Mixed Quarter Clarify or Cloud Its Medicare Advantage Scale Ambitions?
Alignment Healthcare (ALHC) reported a mixed quarter with 44.4% revenue growth and an EPS beat, yet issued weaker-than-expected revenue guidance, causing an 8.5% share price drop. The company continues to emphasize expanding its Medicare Advantage offerings and national footprint, supported by a recent US$256.2 million follow-on equity offering. This article explores how these results and future guidance impact the investment narrative, highlighting the balance between growth, profitability, and market risks.
Alignment healthcare exec Joyce sells $320k in shares
Christopher J. Joyce, Chief Legal and Admin. Officer at Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 18,013 shares of common stock for a total of $320,492. The sale occurred on April 1, 2026, at a weighted-average price of $17.7923 per share. Despite the company's year-to-date stock decline of 9.6%, analysts predict profitability this year and strong revenue growth, with firms like Raymond James and Piper Sandler maintaining "Strong Buy" and "Overweight" ratings respectively.
Alignment healthcare exec Joyce sells $320k in shares
Christopher J. Joyce, Chief Legal and Admin. Officer at Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 18,013 shares of common stock for a total of $320,492 on April 1, 2026. This transaction follows recent strong financial performance by Alignment Healthcare, including 25% year-over-year membership growth and a 44.4% revenue increase in Q4, and a secondary offering of 13.2 million shares by an affiliate of General Atlantic. Analysts maintain "Strong Buy" and "Overweight" ratings for ALHC, with price targets ranging from $27.00 to $30.00.
Christopher Joyce Sells 18,013 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock
Christopher Joyce, an insider at Alignment Healthcare (NASDAQ:ALHC), sold 18,013 shares of the company's stock on April 1st, reducing his stake by 5.57%. This transaction was valued at approximately $320,451. Despite this insider sale, the company reported better-than-expected Q4 earnings and maintains a "Moderate Buy" consensus rating from analysts with an average target price of $24.56.
Alignment Healthcare to Present at the BofA Securities Health Care Conference 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) announced it will present at the BofA Securities Health Care Conference 2026 on Wednesday, May 13, at 8:40 a.m. PDT in Las Vegas. A webcast and replay of the presentation will be available on the company's investor relations website. The company focuses on senior care through its Medicare Advantage plans, aiming to provide high-quality, low-cost care.
Alignment Healthcare (ALHC) legal chief sells stock under 10b5-1 plan
Christopher J. Joyce, Chief Legal and Admin. Officer of Alignment Healthcare (ALHC), sold 18,013 shares of common stock in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. The sale was executed at a weighted-average price of $17.7923 per share, totaling approximately $320,493. After the transaction, Mr. Joyce directly holds 305,451 shares of Alignment Healthcare.
10b5-1 sales reported for ALHC (NASDAQ: ALHC) — 35,736 shares disclosed
An executive of Alignment Healthcare, Inc. (NASDAQ: ALHC), Christopher J. Joyce, filed a Form 144 disclosing proposed sales of 35,736 shares of common stock. These sales were made under a 10b5-1 plan and included two transactions: 10,611 shares sold on January 2, 2026, for $212,590.32, and 25,125 shares sold on March 18, 2026, for $448,230.00. The filing also detailed Performance Stock Units and Restricted Stock Units as the source of these shares.
Alignment Healthcare Stock Sinks on Medicare Payment Shock
Alignment Healthcare (ALHC) stock experienced a drop due to the Centers for Medicare & Medicaid Services (CMS) locking in 2027 Medicare Advantage reimbursement rates that saw only a minimal increase of 0.09%. This slight rate hike, which falls behind rising medical costs, raises profitability concerns for companies heavily reliant on government funding for their Medicare Advantage plans. The sell-off in ALHC shares, alongside other Medicare Advantage insurers, reflects broader market anxieties about shrinking margins and prompts analysts to reassess their outlook for these businesses.
Certain Performance Share Units of Alignment Healthcare, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.
Certain Performance Share Units (PSUs) of Alignment Healthcare, Inc. (ALHC) will conclude their 30-day lock-up period on April 1, 2026. This lock-up, starting March 2, 2026, prevents directors and executive officers from disposing of or hedging common stock or convertible securities. The agreement aims to stabilize the stock price after a recent offering.
Certain Common Stock of Alignment Healthcare, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026.
Certain common stock of Alignment Healthcare, Inc. (ALHC) are under a lock-up agreement set to expire on April 1, 2026. This lock-up period began on March 2, 2026, and prevents directors and executive officers from disposing of or hedging common stock or convertible securities for 30 days following the prospectus supplement's date. The company, trading at $18.72, offers Medicare Advantage plans across six states and focuses on a consumer-centric healthcare platform.
JPMorgan Chase & Co. Sells 87,113 Shares of Alignment Healthcare, Inc. $ALHC
JPMorgan Chase & Co. reduced its stake in Alignment Healthcare by 16.2% in Q3, selling 87,113 shares and retaining 449,633 shares valued at $7.85 million. Insiders also engaged in significant selling, totaling 1,432,253 shares worth approximately $27.99 million in the last 90 days. Despite insider sales, Alignment Healthcare exceeded quarterly EPS estimates and reported strong revenue growth, with analysts maintaining a "Moderate Buy" rating and a target price of $24.56.
Tudor Investment Corp ET AL Has $4.76 Million Stake in Alignment Healthcare, Inc. $ALHC
Tudor Investment Corp ET AL significantly reduced its stake in Alignment Healthcare (NASDAQ:ALHC) by 76% in Q3, selling 865,720 shares and now holding 273,010 shares valued at approximately $4.76 million. While large institutions like Vanguard and Wellington increased their positions, institutional ownership stands at 86.19%. Insiders have been net sellers, disposing of 2,418,393 shares worth $46.47 million in the last three months, though analysts have an average "Moderate Buy" rating with a target price of $24.56.
Vanguard Holdings Update — Alignment Healthcare (NASDAQ: ALHC) shows 0 shares
The Vanguard Group has filed an Amendment No. 4 to a Schedule 13G/A, reporting 0 beneficial shares (0%) in Alignment Healthcare (ALHC). This change is attributed to an internal realignment within Vanguard, effective January 12, 2026, where several subsidiaries will now report beneficial ownership separately. The filing is administrative and not indicative of a transaction, with minimal market impact expected.
CEO Planned Share Sale And Alignment Healthcare Valuation Gap
Alignment Healthcare CEO John E. Kao has initiated a preplanned sale of 118,000 shares, though he retains a significant stake. This transaction occurs amidst mixed stock performance, including recent declines, despite the company's valuation appearing significantly below analyst targets and Simply Wall St's fair value estimation. Investors are advised to consider this alongside fundamental analysis and the company's existing risk flag regarding substantial insider selling.
CEO Planned Share Sale And Alignment Healthcare Valuation Gap
Alignment Healthcare CEO John E. Kao has arranged the indirect sale of 118,000 shares through a predetermined trading program. This event occurs while the stock shows mixed performance, including recent declines, and trades significantly below analyst targets and Simply Wall St's fair value estimate. Investors are advised to consider this alongside fundamental data and market sentiment.
Alignment Healthcare, Inc. (NASDAQ:ALHC) Given Consensus Rating of "Moderate Buy" by Brokerages
Alignment Healthcare, Inc. (NASDAQ:ALHC) has received a "Moderate Buy" consensus rating from brokerages, with an average one-year target price of $24.56. While the company recently beat EPS estimates and showed strong revenue growth, it still faces a negative net margin and anticipated negative EPS for the fiscal year. Recent insider selling of over 2.4 million shares worth approximately $46.5 million has also been noted.
Alignment Healthcare CEO Sells $2.1 Million in Shares. Here's What Investors Should Know
Alignment Healthcare's CEO, John E. Kao, indirectly sold 118,000 shares worth $2.06 million on March 23, 2026, as part of a pre-arranged trading plan. This sale represents a small portion of his total holdings, which remain over 4.1 million shares. Investors are advised to focus on the company's ability to achieve consistent profitability and margin expansion despite strong revenue and membership growth.
Alignment Healthcare’s (ALHC) CEO Kao sells $2m in stock
Alignment Healthcare's CEO, John E. Kao, sold 118,000 shares of common stock for over $2 million on March 23, 2026, as part of a pre-arranged trading plan. The company, valued at $3.59 billion despite an 11% year-to-date decline, has shown strong revenue growth and is predicted by analysts to be profitable this year. Recent positive fourth-quarter results and analyst ratings, alongside a secondary offering, highlight various financial activities and investor interest.
Assessing Alignment Healthcare (ALHC) Valuation After Recent Share Price Weakness
Alignment Healthcare (ALHC) has experienced recent stock price weakness, declining 13.4% year to date and 15% over the past month, but it is currently valued at US$17.51, representing a 67% intrinsic discount and sitting 46% below the average analyst price target. The company's fair value is estimated at $25.42 due to its technology-enabled care model, potential for margin expansion, and growth prospects in the senior care market, despite potential risks from Medicare Advantage reimbursement changes and increased competition. Investors are encouraged to review the company's data, including potential rewards and warning signs, to make an informed decision.
John Kao Sells 118,000 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock
John Kao, CEO of Alignment Healthcare (NASDAQ:ALHC), sold 118,000 shares of the company's stock on March 23, 2026, for approximately $2.06 million, reducing his stake by 4.77%. Despite the insider selling, institutional investors hold a significant portion of the company's shares. Analysts collectively rate ALHC as a "Moderate Buy" with an average target price of $24.56, while the company reported better-than-expected quarterly earnings but still shows a negative net margin.
Alignment Healthcare (ALHC) CEO’s trust sells 118K shares under Rule 10b5-1 plan
Alignment Healthcare's CEO, John E. Kao, indirectly sold 118,000 shares of common stock through the JEK Trust at a weighted-average price of $17.4783 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the transaction, Kao retains substantial holdings, both indirectly through the trust and directly, suggesting the sale was part of routine portfolio management rather than a major change in his equity exposure.
John E. Kao (ALHC) reports multiple 10b5-1 stock sales through March 2026
John E. Kao, an insider at Alignment Healthcare, Inc. (ALHC), has reported multiple stock sales of Common stock under 10b5-1 plans through March 2026. These routine dispositions include transactions made by Kao personally and by the JEK Trust U/A DTD 02/08/2021, totaling significant amounts like $1,133,514.66 on December 29, 2025, and repeated sales of $3,273,558.00 in early 2026. The Form 144 filing indicates these are pre-arranged trades, not reflective of new corporate developments or operational changes for ALHC.
Hudson Bay Capital Management LP Acquires New Holdings in Alignment Healthcare, Inc. $ALHC
Hudson Bay Capital Management LP has acquired a new stake in Alignment Healthcare, purchasing 262,500 shares valued at approximately $4.58 million in the third quarter. Despite this new institutional investment and strong Q4 revenue performance that beat analyst estimates, the company faces clustered insider selling and a secondary offering by a major shareholder, creating potential near-term selling pressure and headline risk for the stock. Analysts currently hold a "Moderate Buy" consensus rating with a target price of $24.56.
Alignment Healthcare (ALHC) president sells shares to cover RSU tax withholding
Alignment Healthcare, Inc. President Dawn Christine Maroney sold 36,749 shares of common stock to cover tax withholding obligations arising from vesting restricted stock units. The sale was non-discretionary and executed on the open market at a weighted-average price of $17.84 per share. Following this transaction, Maroney retains a direct holding of 1,058,813 shares in the company.
Alignment Healthcare (ALHC) CMO sells 18,404 shares to cover taxes
Alignment Healthcare's Chief Medical Officer, Hyong Kim, sold 18,404 shares of common stock at a weighted-average price of $17.84 per share. This sale was explicitly stated to cover tax withholding obligations from vested restricted stock units, not a discretionary trade. Following the transaction, Kim directly holds 367,701 shares of Alignment Healthcare common stock.
Alignment Healthcare (ALHC) CLO sells stock to cover RSU tax obligations
Christopher J. Joyce, Chief Legal and Administrative Officer of Alignment Healthcare, Inc. (ALHC), sold 25,125 shares of common stock on March 18, 2026. This sale was explicitly to cover tax withholding obligations related to the vesting of restricted stock units and was not a discretionary trade. After the transaction, Joyce directly holds 323,464 shares of Alignment Healthcare common stock.
Alignment Healthcare (NASDAQ: ALHC) COO sells 15,361 shares for tax withholding
Alignment Healthcare's COO, Sebastian Burzacchi, sold 15,361 shares of common stock at a weighted-average price of $17.84 per share. This transaction was non-discretionary and executed solely to cover tax withholding obligations associated with the vesting of restricted stock units. After the sale, Burzacchi retains direct ownership of 258,630 shares in the company.
Alignment Healthcare (ALHC) CIO sells 11,285 shares to cover RSU tax
Alignment Healthcare's Chief Information Officer, Robert L. Scavo, sold 11,285 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting. This transaction was not a discretionary trade, and the shares were sold at a weighted-average price of $17.84. Following this sale, Scavo directly holds 487,685 shares of Alignment Healthcare common stock.
Alignment Healthcare (ALHC) CEO sells shares to cover RSU tax withholding
Alignment Healthcare CEO John E. Kao sold 73,046 shares of common stock at a weighted-average price of $17.84 per share. This sale was explicitly stated to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) and was not a discretionary trade. Following this transaction, Kao retains significant direct and indirect holdings in the company.
Alignment Healthcare (NASDAQ:ALHC) President Sells $655,602.16 in Stock
Alignment Healthcare (NASDAQ:ALHC) President Dawn Christine Maroney sold 36,749 shares of the company's stock for $655,602.16 on March 18th, reducing her stake by 3.35%. This is part of a pattern of significant insider sales from Maroney and other executives, which is raising sentiment risks despite the company beating recent earnings estimates and analysts raising price targets on the stock. Institutional investors, however, have been increasing their positions in ALHC.
Alignment Healthcare (NASDAQ:ALHC) COO Sells $274,040.24 in Stock
Alignment Healthcare's COO, Sebastian Burzacchi, sold 15,361 shares worth $274,040.24, reducing his stake by 5.61%. This sale is part of a cluster of insider liquidations by senior executives, which could negatively impact investor sentiment despite the company's strong operational performance and positive analyst ratings. Alignment Healthcare (ALHC) recently beat quarterly EPS and revenue estimates, and several analysts have raised their price targets, resulting in a consensus "Moderate Buy" rating.
Alignment Healthcare (NASDAQ:ALHC) Insider Hyong Kim Sells 18,404 Shares
Alignment Healthcare insider Hyong Kim sold 18,404 shares of the company's stock for approximately $328,327, reducing his holdings by 4.77%. This sale, along with other insider liquidations, might negatively impact investor sentiment despite the company recently beating quarterly earnings estimates and maintaining a "Moderate Buy" consensus rating from analysts.
Wagner, Alignment healthcare CHRO, sells $425k in ALHC stock
Andreas P. Wagner, Chief Human Resources Officer at Alignment Healthcare (NASDAQ:ALHC), sold a total of 23,602 shares of common stock across two transactions, totaling approximately $425,476. These sales included shares covering tax withholding obligations and shares sold under a pre-arranged 10b5-1 trading plan. Following these sales, Wagner directly owns 148,628 shares, while the company has also seen recent positive analyst ratings and a secondary offering of shares from an affiliate.
Institutional Control And Insider Selling Shape Alignment Healthcare Risk Picture
Alignment Healthcare (NasdaqGS:ALHC) shows a complex risk-reward profile due to its high institutional ownership (86%) and recent insider selling by Director Robert Scavo. The company focuses on Medicare Advantage plans, attracting long-term interest from large funds, but the insider sale raises questions about management's confidence. Investors should monitor institutional ownership changes, future insider activity, and share price reactions to policy updates to assess the company's future trajectory.
Alignment Healthcare’s idiosyncratic take on Medicare Advantage
Alignment Healthcare CEO John Kao discusses his company's unique approach to Medicare Advantage, emphasizing clinically oriented care and data analytics to manage high-cost members. Despite an industry-wide slowdown and flat proposed MA rates, Alignment expects continued growth by focusing on quality ratings, controlled medical costs, and strategic expansion. Kao also addresses industry practices like risk adjustment gaming and his optimistic outlook on future MA payment rates.
Alignment Healthcare, Inc. (NASDAQ:ALHC) Q4 2025 earnings call transcript
This article provides the Q4 2025 earnings call transcript for Alignment Healthcare, Inc. (NASDAQ:ALHC). It details the financial results and discussions from the company's conference call with investors and analysts. The transcript offers insights into Alignment Healthcare's performance during the fourth quarter of 2025.
Alignment Healthcare (ALHC) CHRO receives 23,543 restricted stock units in equity grant
Alignment Healthcare (ALHC) Chief Human Resources Officer, Andreas P. Wagner, received an equity grant of 23,543 restricted stock units (RSUs). These RSUs, each representing one share of common stock, will vest in approximately one-third increments on the first three anniversaries of the grant date, contingent on his continued service. Following this transaction, Wagner directly holds 172,230 shares of Alignment Healthcare common stock.
Alignment Healthcare (ALHC) grants 51,501 RSUs to chief legal officer
Alignment Healthcare, Inc. (ALHC) granted 51,501 restricted stock units (RSUs) to its Chief Legal and Administrative Officer, Christopher J. Joyce, as part of his compensation. These RSUs will vest in approximately one-third installments on the first three anniversaries of the grant date, provided he remains with the company. Following this grant, Joyce directly holds 348,589 shares of the company's common stock.
Alignment Healthcare (ALHC) awards 25,015 RSUs to Chief Digital Officer
Alignment Healthcare (ALHC) has awarded its Chief Digital Officer, Adnan R. Mansour, 25,015 restricted stock units (RSUs) as part of his equity compensation. These RSUs will vest in approximately one-third increments on each of the first three anniversaries of the grant date, provided Mansour continues his service to the company. Following this grant, Mansour directly holds 48,456 shares or units tied to Alignment Healthcare stock.
Yorkville Advisors Global LP Purchases Shares of 75,000 Alignment Healthcare, Inc. $ALHC
Yorkville Advisors Global LP has acquired a new position of 75,000 shares in Alignment Healthcare (NASDAQ:ALHC) during the third quarter, valued at approximately $1.31 million. This makes Alignment Healthcare the firm's 12th largest holding. The company reported strong financial results, beating EPS estimates and showing significant year-over-year revenue growth, leading analysts to rate it a "Moderate Buy."
Alignment Healthcare, Inc. (NASDAQ:ALHC) Q4 2025 earnings call transcript
This document is a transcript of Alignment Healthcare, Inc.'s Q4 2025 earnings call. It contains details of the company's financial performance and discussions from the call.
Dawn Christine Maroney Sells 30,000 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock
Dawn Christine Maroney, President of Alignment Healthcare (NASDAQ:ALHC), sold 30,000 shares of the company's stock on March 16th at an average price of $17.48, totaling $524,400. This transaction reduced her stake by 2.67% to 1,095,562 shares. The sale is part of a series of insider dispositions dating back to December, despite the stock rising by approximately 2.3% and the company beating earnings estimates with strong revenue growth.
Alignment Healthcare (ALHC) grants CFO 103,002 restricted stock units
Alignment Healthcare (ALHC) has granted its CFO, James M. Head, 103,002 restricted stock units (RSUs). These RSUs will vest in approximately equal one-third portions on each of the first three anniversaries of the grant date, contingent on his continued employment. Following this grant, Head's direct holdings in Alignment Healthcare common stock now total 184,595 shares.
